Here is a brief summary of our evolution and successes.
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2007
2006
2004
2003
2001
2000
1997
2024
Entered into a drug discovery collaboration with Hox Therapeutics
Entered into a drug discovery collaboration in inflammatory disease with C4X Discovery
2023
Entered into a long-term, multi-target research collaboration with Pierre Fabre to identify pre-clinical candidates against a range of oncology targets
Dania Therapeutics, co-founded by Vernalis in 2021 to develop a treatment for acute myeloid leukaemia (AML), receives an investment of DKK 15 million from a syndicate of investors
2022
Entered into a research collaboration with Unison Medicines, working on a “undruggable” anti-infective target. Vernalis also invested in Unison’s first round of financing
Entered into a strategic research collaboration with Contera Pharma, targeting an undisclosed neurology target through small molecule-RNA interactions
Developed a novel platform technology, PAC-FragmentDEL, combining the diversity of fragment-based drug discovery with the sensitivity of DNA-encoded library technology
Achieved two research and one pre-clinical milestones in an oncology drug discovery collaboration with Servier, triggering undisclosed milestone payments to Vernalis
Vernalis and Hannibal Innovation ApS announced the creation of Dania Therapeutics ApS to discover small molecules inhibitors against new undisclosed oncology targets
2020
Announced the achievement of a milestone in the most recent oncology drug discovery collaboration with Servier, established in 2017 on an undisclosed target
Expanded the oncology research collaboration with Servier. The new three-year research collaboration combined Vernalis’ strengths in structure and biophysics-based methods with oncology expertise at Servier, to enable drug discovery related to several undisclosed proteins identified as potential therapeutic targets
Entered into a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialise VER250840, a novel, oral, selective, preclinical Chk1 kinase inhibitor
Entered into a research collaboration agreement with PhoreMost on an undisclosed novel oncology target, identified and validated using its phenotypic screening technology
Success milestones achieved under drug discovery collaboration with Daiichi Sankyo on two undisclosed oncology targets
Achieved third success milestone from drug discovery collaboration with Asahi Kasei Pharma on an undisclosed target for rheumatoid arthritis and other autoimmune diseases
2017
Achieved 3 milestones in oncology drug discovery collaboration with Servier, including Mcl-1 clinical candidate first time in man, and entered into a fifth research collaboration
Achieved a clinical milestone from an adenosine A2A receptor antagonist collaboration with Corvus Pharmaceuticals, who announced positive data from a Phase 1/1b study with single agent CPI-444 in patients with renal cell carcinoma
Entered into research collaboration with Daiichi Sankyo on undisclosed oncology targets
2016
Achieved milestone in collaboration with Servier for Bcl-2 clinical candidate first time in man
V158866, the lead molecule arising from our FAAH internal research programme, completed a phase II study in spinal cord injury patients
Licensed proprietary adenosine receptor antagonist technology, including lead A2A antagonist V81444 (later CPI-444), for development and commercialisation to Corvus Pharmaceuticals
2014
Awarded a Queen’s Award for Enterprise in International Trade, endorsing both our talent and capabilities, and recognising achievement in growing overseas earnings through research collaborations
Licensed worldwide rights in vipadenant, a small molecule A2A receptor antagonist, for use in immuno-oncology to RedoxTherapies (a BMS company)
Entered into a fourth research collaboration with Servier
2013
Achieved a third milestone in a drug discovery collaboration with H. Lundbeck A/S
Entered into a research collaboration with Asahi Kasei Pharma on an undisclosed target for rheumatoid arthritis and other autoimmune diseases
2012
Entered into a drug discovery collaboration with Genentech (now completed) utilising Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target
Achieved a pre-clinical milestone in the first oncology research collaboration with Servier
2011
Positive results obtained from a Phase I trial of V158866, a FAAH inhibitor with potential application in a wide range of pain and other indications
Two milestones from research collaboration with H. Lundbeck A/S on LRRK2 inhibitors obtained
Entered into a third research collaboration with Servier
2010
Entered into a collaboration with H. Lundbeck A/S on LRRK2, inhibitors of which have utility for the treatment of Parkinson’s disease
2009
Entered into a collaboration with GlaxoSmithKline (now completed) over a novel Vernalis oncology programme
Entered into a second oncology research collaboration with Servier
2007
First research collaboration with Servier (which is still active); growing expertise in biophysical methods such as ITC and SPR
2006
Research concentrated on Granta Park site with in-house projects on oncology targets
2004
Hsp90 pre-clinical candidate partnered with Novartis, although this has since terminated and the rights have been returned to Vernalis
2003
Series of mergers created Vernalis plc, combining the expertise of RiboTargets with CNS targets and GPCR pharmacology from Vernalis Group in Winnersh, as well as DMPK capability, a clinical pipeline and a marketed product, frovatriptan
2001
Research changed focus to oncology protein targets; development of the SeeDs fragment-based discovery platform
2000
Structure-based discovery of inhibitors of the 30S subunit of the ribosome; established X-ray crystallography
1997
RiboTargets established fragment- and structure-based drug discovery against RNA targets; established macromolecular NMR spectroscopy
This website uses cookies.
Like other organisations, we use “cookies” on our website to collect information about how the site is used. A cookie is a small file of letters and numbers that we store on your browser or the hard drive of your computer if you agree. Cookies contain information that is transferred to your computer’s hard drive. Find out more